

Special Issue

Theranostic Drug Delivery: Prospects and Problems

Message from the Guest Editor

Theranostic drug delivery exploits the combined properties of diagnosis and therapy and as such can benefit the development of targeted drug delivery systems and modern personalized medicine. The theranostic approach is used to design and formulate biocompatible and smart protocols for controlled, stimuli-responsive gene or drug delivery for various applications. It is expected that the success of theranostics will depend on multidisciplinary efforts, combined to expedite our understanding of host responses to customized theranostic agents and formulating individualized therapies. This Special Issue aims to provide an up-to-date collection of original research articles and review papers on the development of novel targeted drug delivery systems for the encapsulation and delivery of chemotherapeutic reagents, DNA- and RNA-based molecules, peptides, and other bioactive compounds. The themed issue will encompass significant efforts aimed at using biological language to discern between “friends” and “foes” in the context of theranostics for accurate clinical applications.

Guest Editor

Prof. Dr. M. R. Mozafari

Australasian Nanoscience and Nanotechnology Initiative (ANNI),
Monash University LPO, Clayton 3800, Australia

Deadline for manuscript submissions

closed (30 June 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/49266

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).